Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Found 2996 publications
Research on China Cardiovascular Drugs Industry, 2014-2018 US$ 2,500.00

Research on China Cardiovascular Drugs Industry, 2014-2018 primarily carries on analyses on cardiovascular drugs market in the following aspects: market scale, the ... . In the next ten years, there is a potential for the growth in cardiovascular diseases treatment field. It is predicted that the growth rate will ...

May, 2014 85 pages
Zolmitriptan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... basis SAVE VAST AMOUNTS OF TIME Complete, reliable and verifiable data so you don’t have to fill holes and double check Intelligent, ... registers is provided at no additional charge. ABOUT GENERICSWEB: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from ...

Jul, 2014
Zoledronic Acid - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Add your own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Zoledronic Acid indications: Bone damage due to malignancies innovator: Novartis (Zometa) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Ziprasidone - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... basis SAVE VAST AMOUNTS OF TIME Complete, reliable and verifiable data so you don’t have to fill holes and double check Intelligent, ... registers is provided at no additional charge. ABOUT GENERICSWEB: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from ...

Jul, 2014
Vortioxetine - Comprehensive patent search US$ 7,500.00

... , save searches and results THIS REPORT COVERS: International Nonproprietary Name: Vortioxetine indications: Treatment of major depressive disorder and generalised anxiety disorder innovator:Takeda; Lundbeck COUNTRY COVERAGE: The In-depth search contains patents from territories that are individually ...

Jul, 2014
Voriconazole - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... searches and results THIS REPORT COVERS: International Nonproprietary Name: Voriconazole indications: Treatment of aspergillosis; serious Candida infections; serious refractory fungal infections. innovator: Pfizer (Vfend) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina ...

Jul, 2014
Vildagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... THIS REPORT COVERS: International Nonproprietary Name: Vildagliptin indications: Treatment of type 2 diabetes mellitus, optionally in combination with Metformin, a sulphonylurea, a thiazolidinedione or Insulin innovator: Novartis (Galvus, Jalra, Icandra, Xiliarx, Zomarist, Eucreas, Sobrea, Galvumet) ...

Jul, 2014
Vilazodone - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... your own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Vilazodone indications: Treatment of major depressive disorder innovator: Forest (Viibryd) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Venlafaxine - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Venlafaxine indications: Depression; Generalised anxiety disorder innovator: Wyeth (Effexor, Efexor) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Vardenafil - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... basis SAVE VAST AMOUNTS OF TIME Complete, reliable and verifiable data so you don’t have to fill holes and double check Intelligent, ... registers is provided at no additional charge. ABOUT GENERICSWEB: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from ...

Jul, 2014
Vandetanib - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... results THIS REPORT COVERS: International Nonproprietary Name: Vandetanib indications: Treatment of medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease innovator: IPR (Caprelsa), Astrazeneca (Caprelsa, Zactima) COUNTRY COVERAGE: Albania Australia Austria ...

Jul, 2014
Vandetanib - Comprehensive patent search US$ 9,300.00

... and results THIS REPORT COVERS: International Nonproprietary Name: Vandetanib indications: Treatment of medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease innovator:IPR (Caprelsa), Astrazeneca (Caprelsa, Zactima) COUNTRY COVERAGE: The In-depth search contains ...

Jul, 2014
Valsartan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Valsartan indications: Hypertension; Hypertension (with HCTZ) innovator: Novartis (Diovan, Diovan HCT, Co-Diovan) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria ...

Jul, 2014
Valganciclovir - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source ... : Valganciclovir indications: Treatment of cytomegalovirus (CMV) retinitis in patients with AIDS; Prophylaxis of CMV infection/disease after solid organ transplant. innovator: Roche ...

Jul, 2014
Topiramate - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... results THIS REPORT COVERS: International Nonproprietary Name: Topiramate indications: Epilepsy; Generalised tonic-clonic seizures; Seizures in Lennox-Gastaut syndrome; Prophylaxis of Migraine headache innovator: Ortho-McNeil (Topamax); Janssen (Topamax) COUNTRY COVERAGE: Albania Australia Austria ...

Jul, 2014
Tolterodine - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Tolterodine indications: Urinary frequency, urgency and incontinence innovator: Pharmacia (Detrol, Detrusitol) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria ...

Jul, 2014
Tofacitinib - Comprehensive patent search US$ 7,500.00

... and results THIS REPORT COVERS: International Nonproprietary Name: Tofacitinib indications: In combination with Methotrexate, or other non-biological disease-modifying anti-rheumatic drugs for the treatment of moderate to severe active rheumatoid arthritis innovator:Roche (RoActemra, Actemra) COUNTRY ...

Jul, 2014
Tigecycline - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of ... Nonproprietary Name: Tigecycline indications: Complicated skin and skin structure infections; Complicated intra-abdominal infections innovator: Wyeth(Tygacil) COUNTRY COVERAGE: ...

Jul, 2014
Ticagrelor - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results THIS REPORT COVERS: International Nonproprietary Name: Ticagrelor indications: Prevention of thrombotic events in a patient with acute coronary syndromes, optionally in combination with Aspirin innovator: AstraZeneca (Brilinta, Possia, Brilique) COUNTRY COVERAGE: Australia Canada France ...

Jul, 2014
Ticagrelor - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... results THIS REPORT COVERS: International Nonproprietary Name: Ticagrelor indications: Prevention of thrombotic events in a patient with acute coronary syndromes, optionally in combination with Aspirin innovator: AstraZeneca (Brilinta, Possia, Brilique) COUNTRY COVERAGE: Albania Australia Austria ...

Jul, 2014
Ticagrelor - Comprehensive patent search US$ 7,500.00

... results THIS REPORT COVERS: International Nonproprietary Name: Ticagrelor indications: Prevention of thrombotic events in a patient with acute coronary syndromes, optionally in combination with Aspirin innovator:AstraZeneca (Brilinta, Possia, Brilique) COUNTRY COVERAGE: The In-depth search contains ...

Jul, 2014
Temsirolimus - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Add your own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Temsirolimus indications: Advanced renal cell carcinoma. innovator: Wyeth (Torisel) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Telmisartan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Telmisartan indications: Hypertension innovator: Boehringer Ingelheim (Micardis, Micardis HCT, Micardis Plus, Pritor) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria ...

Jul, 2014
Tamsulosin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... searches and results THIS REPORT COVERS: International Nonproprietary Name: Tamsulosin indications: Benign prostatic hyperplasia; Urinary disorders innovator: Boehringer Ingelheim (Flomax); Yamanouchi (Flomax); CSL (Flomax) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina ...

Jul, 2014
Tadalafil - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Add your own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Tadalafil indications: Male erectile dysfunction, Impotence innovator: Lilly (Cialis) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Tacrolimus - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Tacrolimus indications: Immunosuppressant; Eczema innovator: Fujisawa (Prograf, Protopic); Janssen-Cilag (Prograf) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria ...

Jul, 2014
Sunitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Sunitinib indications: Gastrointestinal stromal tumour; advanced renal cell carcinoma innovator: Pfizer(Sutent) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada ...

Jul, 2014
Sugammadex - Comprehensive patent search US$ 7,500.00

... and results THIS REPORT COVERS: International Nonproprietary Name: Sugammadex indications: Reversal of neuromuscular blockade induced by Rocuronium or Vecuronium innovator:Organon (Bridion); Merck (Bridion) COUNTRY COVERAGE: The In-depth search contains patents from territories that are individually ...

Jul, 2014
Sitagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source ... : Sitagliptin indications: Improvement of glycemic control in patients with type 2 diabetes mellitus; used alone or in combination with Metformin or a PPARy agonist. innovator: Merck ...

Jul, 2014
Simvastatin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Simvastatin indications: Hypercholesterolemia, Hyperlipidemia innovator: Merck (Zocor, Lipex, Simvar) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada ...

Jul, 2014
Silodosin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Silodosin indications: Benign prostatic hypertropy innovator: Kissei (Urief); Watson (Rapaflo) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Sildenafil - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Sildenafil indications: Male erectile dysfunction; pulmonary arterial hypertension, angina innovator: Pfizer (Viagra, Revatio) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil ...

Jul, 2014
Saxagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... THIS REPORT COVERS: International Nonproprietary Name: Saxagliptin indications: Treatment of type 2 diabetes mellitus optionally in combination with Metformin, a sulphonylurea or a thiazolidinedione innovator: Bristol-Myers Squibb (Onglyza, Kombiglyze); AstraZeneca (Onglyza) COUNTRY COVERAGE: Albania ...

Jul, 2014
Saxagliptin - Comprehensive patent search US$ 7,500.00

... THIS REPORT COVERS: International Nonproprietary Name: Saxagliptin indications: Treatment of type 2 diabetes mellitus optionally in combination with Metformin, a sulphonylurea or a thiazolidinedione innovator:Bristol-Myers Squibb (Onglyza, Kombiglyze); AstraZeneca (Onglyza) COUNTRY COVERAGE: The In- ...

Jul, 2014
Rosuvastatin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... THIS REPORT COVERS: International Nonproprietary Name: Rosuvastatin indications: Hyperlipidemia; Mixed Dyslipidemia; Hypertriglyceridemia; Homozygous Familial Hypercholesterolemia; Atherosclerosis innovator: AstraZeneca (Crestor, Visacor) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia ...

Jul, 2014
Rosiglitazone - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... searches and results THIS REPORT COVERS: International Nonproprietary Name: Rosiglitazone indications: Type 2 diabetes mellitus innovator: GSK (Avandia, Avaglim, Avandamet); SB Pharmco (Avandia, Avandaryl, Avandamet) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil ...

Jul, 2014
Ropinirole - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... searches and results THIS REPORT COVERS: International Nonproprietary Name: Ropinirole indications: Parkinson's disease; restless legs syndrome innovator: GlaxoSmithKline (Requip, Repreve, Adartrel, Ardentel and Vunexin ) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina ...

Jul, 2014
Rizatriptan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Add your own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Rizatriptan indications: Treatment of acute migraine attacks innovator: Merck (Maxalt) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Rivastigmine - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... basis SAVE VAST AMOUNTS OF TIME Complete, reliable and verifiable data so you don’t have to fill holes and double check Intelligent, ... registers is provided at no additional charge. ABOUT GENERICSWEB: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from ...

Jul, 2014
Rivaroxaban - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Nonproprietary Name: Rivaroxaban indications: Prevention of venous thromboembolism in adult patients who are undergoing elective hip or knee replacement surgery or who have undergone major orthopaedic surgery of the lower limps; Deep vein thrombosis; Pulmonary embolism innovator: Bayer ...

Jul, 2014
Risedronic Acid - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of patent ... Name: Risedronic Acid indications: Osteoporosis, Paget's disease of bone innovator: Procter & Gamble (Actonel, Actonel with Calcium); Aventis (Actonel) COUNTRY COVERAGE: ...

Jul, 2014
Remifentanil - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Name: Remifentanil indications: Analgesic used during induction, maintenance and immediate postoperative period of general anaesthesia in combination with other anaesthetics; Analgesic component of monitored anaesthesia innovator: GlaxoSmithKline (Ultiva); Bioniche (Ultiva); Abbott Labs (Ultiva) COUNTRY ...

Jul, 2014
Rasagiline - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source ... : Rasagiline indications: Treatment of the signs and symptoms of idiopathic Parkinson’s disease as initial monotherapy and as adjunct therapy to Levodopa. innovator: Teva (Azilect) ...

Jul, 2014
Ranelic Acid - Comprehensive patent search US$ 7,500.00

... and results THIS REPORT COVERS: International Nonproprietary Name: Ranelic Acid indications: Treatment of osteoporosis in postmenstrual women to reduce the risk of fractures, optionally in combination with Vitamin D and/or Calcium innovator:Servier (Protelos, Protos, Osseor) COUNTRY COVERAGE: The In- ...

Jul, 2014
Ramelteon - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... basis SAVE VAST AMOUNTS OF TIME Complete, reliable and verifiable data so you don’t have to fill holes and double check Intelligent, ... registers is provided at no additional charge. ABOUT GENERICSWEB: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from ...

Jul, 2014
Raltegravir - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source ... Nonproprietary Name: Raltegravir indications: In combination with other antiretroviral agents for the treatment of HIV-1 infection innovator: Merck (Isentress) COUNTRY COVERAGE: ...

Jul, 2014
Rabeprazole - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source ... : International Nonproprietary Name: Rabeprazole indications: Peptic ulcers; GORD/GERD innovator: Janssen Cilag (Pariet); Eisai (Aciphex) COUNTRY COVERAGE: Albania Australia ...

Jul, 2014
Pregabalin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Pregabalin indications: Neuropathic pain, Epilepsy innovator: CP Pharms (Lyrica); Pfizer (Lyrica) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Prasugrel - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Prasugrel indications: Acute coronary sydromes innovator: Daiichi Sankyo (Effient); Eli Lilly (Effient) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada ...

Jul, 2014
Pramipexole - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Pramipexole indications: Parkinson's disease innovator: Boehringer Ingelheim (Mirapex, Sifrol); Pharmacia (Mirapexin) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria ...

Jul, 2014
1 2 3 4 5 >
Skip to top